Skip to main content

Table 2 Hazard ratio (HR) between genotypes and randomisation calculated with the Cox proportional-hazard model

From: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Genotype

Duration of tamoxifen treatment

 

2 years

5 years

 

HR (n)

95% CI

P

HR (n)

95% CI

P

CYP3A5*1/*1, *1/*3

1.00 (16)

  

1.00 (13)

  

CYP3A5*3/*3

2.84 (83)

0.68–11.99

0.15

0.20 (95)

0.07–0.55

0.002

CYP2D6*1/*1

1.00 (72)

  

1.00 (79)

  

CYP2D6*1/*4, *4/*4

0.87 (31)

0.38–1.97

0.74

0.33 (32)

0.08–1.43

0.14

SULT1A1*1/*2, *2/*2

1.00 (71)

  

1.00 (73)

  

SULT1A1*1/*1

0.33 (32)

0.12–0.96

0.04

0.83 (36)

0.29–2.36

0.73

UGT2B15*1/*1

1.00 (17)

  

1.00 (26)

  

UGT2B15*1/*2, *2/*2

1.18 (62)

0.39–3.52

0.77

1.94 (55)

0.53–7.06

0.31

  1. Cases with less than 2 years of follow-up time were excluded. For each randomisation, patients with the proposed 'low-risk' alleles were used as reference. CI, confidence interval.